Neurocrine Biosciences (NBIX): Reiterate Top Mid Cap Pick - BMO

BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after the company released abstracts for the American Society of Reproductive Medicine conference (October 15-19).

The analyst stated that the abstracts reinforce elagolix's strong efficacy profile in women with endometriosis, showing significant improvements on endometrial-associated pain, endometrial morphology, and quality of life observed on treatment. He believes the data continues to support approval for elagolix’s low- and high-doses, and his $1.0B peak sales estimate in endometriosis, with an additional blockbuster opportunity in uterine fibroids ($2.7B peak sales).

No change to the price target of $66.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $54.16 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community